系统综述与网络Meta分析:中重度克罗恩病的一线和二线生物制剂治疗
该系统综述与网络Meta分析纳入中重度克罗恩病成人随机对照试验,间接比较一线(生物制剂初治)与二线(既往抗TNF-α暴露)生物制剂的疗效与安全性。结果显示,初治患者中英夫利西单抗和阿达木单抗诱导向缓解排名最高,既往抗TNF暴露者中阿达木单抗和乌司奴单抗排名最高,乌司奴单抗严重不良事件和感染风险最低。
要点
- 生物制剂初治患者中,英夫利西单抗(SUCRA 0.93)和阿达木单抗(SUCRA 0.75)诱导向临床缓解排名最高,证据质量中等。
- 既往抗TNF暴露患者中,阿达木单抗(SUCRA 0.91)和乌司奴单抗(SUCRA 0.71)诱导向临床缓解排名最高。
- 维持治疗中乌司奴单抗严重不良事件(SUCRA 0.72)和感染(SUCRA 0.71)风险最低。
核心结论
- 间接比较提示,英夫利西单抗或阿达木单抗可能是一线首选药物,乌司奴单抗可能是二线首选药物,用于中重度克罗恩病患者的诱导缓解。
- 需要头对头试验。
研究设计与样本
- 系统综述与网络Meta分析,纳入中重度克罗恩病成人随机对照试验,比较已批准的抗TNF药物、抗整合素药物和抗IL12/23药物(一线或二线)与安慰剂或其他活性药物。
- 采用GRADE方法评估证据质量。
- 未发现头对头试验。
主要发现
- 生物制剂初治患者中,英夫利西单抗(SUCRA 0.93)和阿达木单抗(SUCRA 0.75)诱导向临床缓解排名最高(证据质量中等)。
- 既往抗TNF暴露患者中,阿达木单抗(SUCRA 0.91;低证据质量,限于既往对抗TNF药物有应答或不耐受者)和乌司奴单抗(SUCRA 0.71)诱导向临床缓解排名最高。
- 对诱导治疗有应答的患者中,阿达木单抗(SUCRA 0.97)和英夫利西单抗(SUCRA 0.68)维持缓解排名最高。
- 维持治疗试验中,乌司奴单抗严重不良事件风险最低(SUCRA 0.72),感染风险最低(SUCRA 0.71;与英夫利西单抗并列,SUCRA 0.83)。
关键数值与推荐
- 疗效结局为诱导和维持临床缓解;安全性结局为严重不良事件和感染。
- 排序采用累积排序曲线下面积(SUCRA)概率评估。
- 生物制剂初治患者诱导向缓解:英夫利西单抗SUCRA 0.93,阿达木单抗SUCRA 0.75(证据质量中等)。
- 既往抗TNF暴露患者诱导向缓解:阿达木单抗SUCRA 0.91(证据质量低),乌司奴单抗SUCRA 0.71。
- 维持缓解:阿达木单抗SUCRA 0.97,英夫利西单抗SUCRA 0.68。
临床怎么用
- 原文未据此给出推荐。
局限性
- 未发现头对头试验。
- 需要头对头试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are limited data to inform positioning of agents for treating moderate-severe Crohn's disease (CD). AIM: We assessed comparative efficacy and safety of first-line (biologic-naïve) and second-line (prior exposure to anti-tumour necrosis factor [TNF]-α) agents) biologic therapy for moderate-severe CD, through a systematic review and network meta-analysis, and appraised quality of evidence (QoE) using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. METHODS: We identified randomised controlled trials (RCTs) in adults with moderate-severe CD treated with approved anti-TNF agents, anti-integrin agents and anti-IL12/23 agents, first-line or second-line, and compared with placebo or another active agent. Efficacy outcomes were induction and maintenance of clinical remission; safety outcomes were serious adverse events and infections. Network meta-analyses were performed, and ranking was assessed using surface under the cumulative ranking (SUCRA) probabilities. RESULTS: No head-to-head trials were identified. In biologic-naïve patients, infliximab (SUCRA,0.93) and adalimumab (SUCRA,0.75) were ranked highest for induction of clinical remission (moderate QoE). In patients with prior anti-TNF exposure, adalimumab (SUCRA, 0.91; low QoE, in patients with prior response or intolerance to anti-TNF agents) and ustekinumab (SUCRA, 0.71) were ranked highest for induction of clinical remission. In patients with response to induction therapy, adalimumab (SUCRA, 0.97) and infliximab (SUCRA, 0.68) were ranked highest for maintenance of remission. Ustekinumab had lowest risk of serious adverse events (SUCRA, 0.72) and infection (SUCRA, 0.71; along with infliximab, SUCRA, 0.83) in maintenance trials. CONCLUSION: Indirect comparisons suggest that infliximab or adalimumab may be preferred first-line agents, and ustekinumab a preferred second-line agent, for induction of remission in patients with moderate-severe CD. Head-to-head trials are warranted.
引用
- Singh S, Fumery M, Sandborn WJ, et al. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease. Aliment Pharmacol Ther. 2018. PMID: 29920733. doi:10.1111/apt.14852
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。